Acute Effects of Oxygen Supplementation Among IPF Patients
Launched by GEORGE PAPANICOLAOU HOSPITAL · Sep 27, 2018
Trial Information
Current as of June 09, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Stable IPF patients with no hospitalization, exacerbation or change in regular IPF medication during the last month, who do not present with resting hypoxemia, but manifest exercise induced hypoxemia
- Exclusion Criteria:
- • 1. Major contraindications for CPET conduction
- • 2. Not provision of informed consent -
About George Papanicolaou Hospital
George Papanicolaou Hospital is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a focus on a wide range of therapeutic areas, the hospital is committed to adhering to the highest ethical standards and regulatory guidelines in the conduct of clinical research. The institution prides itself on fostering collaboration among multidisciplinary teams of healthcare professionals, researchers, and patients to facilitate the development of new therapies and interventions. By leveraging state-of-the-art facilities and a patient-centric approach, George Papanicolaou Hospital aims to contribute significantly to the global body of medical knowledge and enhance the quality of care provided to its community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Thessaloníki, , Greece
Patients applied
Trial Officials
Aikaterini Markopoulou, MD, PhD
Study Chair
"G. Papanikolaou" General Hospital, Thessaloniki, Greece
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials